eXoZymes, Inc. (EXOZ) Income Statement
EXOZ 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsEXOZ revenue and net income
EXOZ growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EXOZ quarterly EPS vs estimates
Next report: November 12, 2026.
EXOZ income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $267,382 | — | $147,751 | $59,405 |
| Gross profit | — | −$267,382 | — | −$147,751 | −$59,405 |
| Research & development | $3.7M | $1.9M | $527,480 | $348,084 | $454,454 |
| Sales, general & admin | $5.9M | $4.1M | $1.3M | $984,583 | $838,391 |
| Total operating expenses | $9.7M | $5.7M | $1.8M | $1.2M | $1.2M |
| Operating income | −$9.7M | −$5.9M | −$1.8M | −$1.3M | −$1.3M |
| Interest income | — | — | $100 | $98 | $0 |
| Income before taxes | −$9.3M | −$5.9M | −$2.0M | −$1.3M | −$1.2M |
| Income taxes | −$105,205 | — | $42,267 | $63,559 | — |
| Net income | −$9.2M | −$5.9M | −$2.0M | −$1.4M | −$1.2M |
| EBITDA | −$9.0M | −$5.6M | −$1.8M | −$1.2M | −$1.1M |
| EPS (diluted) | −$1.09 | −$0.24 | −$0.25 | −$0.17 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $137,756 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $74,147 | −$214,362 | $71,603 | $72,256 | $70,503 | $67,567 | $68,878 | $68,145 | — | — | — |
| Gross profit | — | −$74,147 | $214,362 | −$71,603 | −$72,256 | −$70,503 | −$67,567 | −$68,878 | −$68,145 | — | — | — |
| Research & development | $1.4M | $1.1M | $1.1M | $1.2M | $802,991 | $575,016 | $630,303 | $723,487 | $237,395 | $277,582 | $550,340 | $27,936 |
| Sales, general & admin | $1.5M | $1.2M | $1.6M | $1.3M | $1.7M | $1.4M | $2.7M | $888,239 | $1.1M | $730,876 | $504,776 | $363,910 |
| Total operating expenses | $3.0M | $2.3M | $2.9M | $2.5M | $2.5M | $1.9M | $1.9M | $1.5M | $1.3M | $1.0M | $985,047 | $391,846 |
| Operating income | −$3.0M | −$2.4M | −$2.7M | −$2.5M | −$2.5M | −$2.0M | −$2.0M | −$1.6M | −$1.3M | −$1.0M | −$985,047 | −$391,846 |
| Interest income | — | — | — | — | — | — | — | — | — | $0 | $0 | — |
| Interest expense | — | $13,716 | — | $59,185 | $76,557 | — | $32,965 | $44,647 | $29,782 | — | — | — |
| Income before taxes | −$2.9M | −$2.4M | −$2.8M | −$2.3M | −$2.4M | −$1.9M | −$1.8M | −$1.7M | −$1.4M | −$1.0M | −$1.1M | −$520,596 |
| Income taxes | — | — | −$105,205 | — | — | — | −$2,143 | — | $2,144 | — | $42,267 | — |
| Net income | −$2.9M | −$2.4M | −$2.7M | −$2.3M | −$2.4M | −$1.9M | −$1.8M | −$1.7M | −$1.4M | −$1.0M | −$1.1M | −$520,596 |
| EBITDA | −$3.0M | −$2.3M | −$3.0M | −$2.2M | −$2.3M | −$1.8M | −$1.8M | −$1.5M | −$1.3M | −$945,666 | −$997,331 | −$470,873 |
| EPS (diluted) | −$0.33 | −$0.28 | −$0.32 | −$0.27 | −$0.28 | −$0.22 | −$0.24 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | −49.0% | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | −1,439.7% | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | −1,332.8% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EXOZ's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EXOZ financial results
eXoZymes reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $9.2 million. Diluted earnings per share came to −$1.09.
See the EXOZ stock overview for the latest quote and news, or the EXOZ chart for price history and technical indicators.
EXOZ income statement FAQ
Does eXoZymes have revenue?
eXoZymes reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is eXoZymes profitable?
No. eXoZymes reported a net loss of $9.2 million in fiscal 2025.
How much does eXoZymes spend on research and development?
eXoZymes spent $3.7 million on research and development in fiscal 2025.
What are eXoZymes's earnings per share?
eXoZymes earned $-1.09 per diluted share in fiscal 2025, compared with $-0.24 a year earlier.
When will eXoZymes report its next earnings?
eXoZymes is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does eXoZymes's fiscal year end?
eXoZymes's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.